Search research articles
Contact Us
Filters
Showing results (1-10 of 10) with videos related to
Page
of 1
Sort By:
BMC Systems Biology
|
July 2, 2008
Construction of a cancer-perturbed protein-protein interaction network for discovery of apoptosis drug targets
Liang-Hui Chu, Bor-Sen Chen
Cancer Informatics
|
March 5, 2009
Comparisons of robustness and sensitivity between cancer and normal cells by microarray data
Liang-Hui Chu, Bor-Sen Chen
Frontiers in Pharmacology
|
September 18, 2015
Computational drug repositioning for peripheral arterial disease: prediction of anti-inflammatory and pro-angiogenic therapeutics
Liang-Hui Chu, Brian H Annex, Aleksander S Popel
Drug Discovery Today
|
October 7, 2014
Computational systems biology approaches to anti-angiogenic cancer therapeutics
Stacey D Finley, Liang-Hui Chu, Aleksander S Popel
Plos One
|
October 21, 2014
Angiogenesis interactome and time course microarray data reveal the distinct activation patterns in endothelial cells
Liang-Hui Chu, Esak Lee, Joel S Bader, et al.
Physiological Genomics
|
August 23, 2012
Constructing the angiome: a global angiogenesis protein interaction network
Liang-Hui Chu, Corban G Rivera, Aleksander S Popel, et al.
Physiological Genomics
|
June 11, 2015
PADPIN: protein-protein interaction networks of angiogenesis, arteriogenesis, and inflammation in peripheral arterial disease
Liang-Hui Chu, Chaitanya G Vijay, Brian H Annex, et al.
Scientific Reports
|
November 18, 2016
A multiscale computational model predicts distribution of anti-angiogenic isoform VEGF<sub>165b</sub> in peripheral arterial disease in human and mouse
Liang-Hui Chu, Vijay Chaitanya Ganta, Min H Choi, et al.
Analytica Chimica Acta
|
June 19, 2012
Unraveling virus identity by detection of depleted probes with capillary electrophoresis
Chin-Yu Wang, Tzu-Hung Hsiao, Liang-Hui Chu, et al.
Immunotherapy Advances
|
March 21, 2024
Pharmacokinetics, safety, and efficacy of 20% subcutaneous immunoglobulin (Ig20Gly) administered weekly or every 2 weeks in Japanese patients with primary immunodeficiency diseases: a phase 3, open-label study
Hirokazu Kanegane, Akifumi Endo, Satoshi Okada, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 10) with videos related to
Sort By:
Page
of 1
BMC Systems Biology
|
July 2, 2008
Construction of a cancer-perturbed protein-protein interaction network for discovery of apoptosis drug targets
Liang-Hui Chu, Bor-Sen Chen
Cancer Informatics
|
March 5, 2009
Comparisons of robustness and sensitivity between cancer and normal cells by microarray data
Liang-Hui Chu, Bor-Sen Chen
Frontiers in Pharmacology
|
September 18, 2015
Computational drug repositioning for peripheral arterial disease: prediction of anti-inflammatory and pro-angiogenic therapeutics
Liang-Hui Chu, Brian H Annex, Aleksander S Popel
Drug Discovery Today
|
October 7, 2014
Computational systems biology approaches to anti-angiogenic cancer therapeutics
Stacey D Finley, Liang-Hui Chu, Aleksander S Popel
Plos One
|
October 21, 2014
Angiogenesis interactome and time course microarray data reveal the distinct activation patterns in endothelial cells
Liang-Hui Chu, Esak Lee, Joel S Bader, et al.
Physiological Genomics
|
August 23, 2012
Constructing the angiome: a global angiogenesis protein interaction network
Liang-Hui Chu, Corban G Rivera, Aleksander S Popel, et al.
Physiological Genomics
|
June 11, 2015
PADPIN: protein-protein interaction networks of angiogenesis, arteriogenesis, and inflammation in peripheral arterial disease
Liang-Hui Chu, Chaitanya G Vijay, Brian H Annex, et al.
Scientific Reports
|
November 18, 2016
A multiscale computational model predicts distribution of anti-angiogenic isoform VEGF<sub>165b</sub> in peripheral arterial disease in human and mouse
Liang-Hui Chu, Vijay Chaitanya Ganta, Min H Choi, et al.
Analytica Chimica Acta
|
June 19, 2012
Unraveling virus identity by detection of depleted probes with capillary electrophoresis
Chin-Yu Wang, Tzu-Hung Hsiao, Liang-Hui Chu, et al.
Immunotherapy Advances
|
March 21, 2024
Pharmacokinetics, safety, and efficacy of 20% subcutaneous immunoglobulin (Ig20Gly) administered weekly or every 2 weeks in Japanese patients with primary immunodeficiency diseases: a phase 3, open-label study
Hirokazu Kanegane, Akifumi Endo, Satoshi Okada, et al.
Page
of 1